Quality of life after total or partial gastrectomy for primary gastric lymphoma

Figures & data

Table I.  Characteristics of study population.

	QOL group n = 36 (100%)^1	Scopy group n = 33 (92%)^2
Median age at follow-up (range)	67 (47–79)	67 (47–79)
Median observation time, months (range)	107 (34–148)	102 (34–148)
Gender (%)
male	16 (44)	15 (45)
female	20 (56)	18 (55)
Diagnosis, after revised histology^3 (%)
Diffuse large B-cell lymphoma (DLBCL)	17 (47)	14 (42)
Marginal zone lymphoma, transforming to DLBCL	15 (41)	15 (45)
Small B-cell lymphoma unspecified	1 (3)	1 (3)
Marginal zone lymphoma	2 (6)	2 (6)
Unspecified	1 (3)	1 (3)
Stage of disease at inclusion (%)
Stage I	15 (42)	15 (45)
Stage II	4 (11)	3 (9)
Stage III	1 (3)	1 (3)
Stage IV	16 (44)	14 (42)
Performance status (ECOG) at inclusion (%)
ECOG 0	24 (67)	24 (73)
ECOG 1	4 (11)	3 (9)
ECOG 2	3 (8)	2 (6)
ECOG 3	1 (3)	1 (3)
Missing	4 (11)	3 (9)
Type of ventricular surgery (%)
Billroth I	4 (11)	4 (12)
Billroth II	10 (28)	10 (30)
Local resection	3 (8)	3 (9)
Total gastrectomy	10 (28)	9 (28)
No surgery	9 (25)*	8 (21)*
Treatment after surgery (%)	n = 27*	n = 26*
Chemotherapy alone (CHOP, N = 15, MACOP-B, N = 3^4)	18 (67)	17 (65)
Radiotherapy alone (40 Gy/20 fractions)	1 (4)	1 (4)
Combination therapy (CHOP, N = 3)	3 (11)	3 (12)

¹ QOL group (n = 36): all who filled in the EORTC QLQ-C3O and the STO-22.

² Scopy group (n = 33): those who met for the clinical examination.

³ According to the WHO classification [22].

⁴ CHOP: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, MACOP-B: adriamycin, cyclophosphamide, vincristine, methotrexate, bleomycin, prednisolone.

* including one patient who underwent minor duodenal resection only.

Table II.  Results from oesophagoscopy and gastroscopy.

	Oesophagoscopy		Gastroscopy
	Scopy (N = 29)^1	Biopsy (N = 28)^2	Scopy (N = 22)^3	Biopsy (N = 21)^4
Normal	20 (69)	21 (75)	12 (55)	12 (57)
Hernia	4 (14)
Oesophagitis	1 (3)	3 (11)
Barett's metaplasia	2 (7)	4 (14)
Gastritis			8 (36)	4 (19)
Helicob. pylori				2 (9)
Intestinal metastases				1 (5)
Unspecific changes	2 (7)		2 (9)	2 (9)

¹ n does not add to 33, 2 patients declined, 2 were on anti-coagulation therapy.

² n does not add to 33, 3 patients declined, 2 were on anti-coagulation therapy.

³ n does not add to 33, 10 had received total gastrectomy, 1 was on anti-coagulation therapy.

⁴ n does not add to 33, 10 had received total gastrectomy, 2 were on anti-coagulation therapy.

Figure 1.  (a and b) Overall and disease specific survival respectively in patients with stage IE and IIE disease (n = 40) and with stage IV disease (n = 80); (c and d) Overall and disease specific survival respectively in patients below the median age of 63 years (n = 60) and above 63 years (n = 60).

Figure 2.  Treatment specific module, STO22¹, across treatment groups. ¹ Higher scores indicate more symptoms. * p-value<.05, total gastrectomy group vs. partial gastrectomy group. ** p-value≤.05, total gastrectomy group vs. both other groups. # including one patient who underwent minor duodenal resection only.

Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of haematopoietic and lymphoid tissues. Pathology and genetics. WHO classification of tumours. IARC Press, Lyon 2001

 Google Scholar